BNT327 50 mg ml

DRUG2 trials

Sponsors

Bristol-Myers Squibb Services Unlimited Company

Conditions

Gastroesophageal JunctionPreviously Untreated Advanced or Metastatic GastricUnresectable or Metastatic Colorectal CancerUntreatedor Esophageal Adenocarcinoma

Phase 2

ROSETTA Gastric-204: A Blinded, Randomized, Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy in Participants with Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Not yet recruitingCTIS2025-523263-37-00

Bristol-Myers Squibb Services Unlimited CompanyGastroesophageal Junction, or Esophageal Adenocarcinoma, Previously Untreated Advanced or Metastatic Gastric

Target: 40Updated: 2026-03-10

ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Not yet recruitingCTIS2025-523224-45-00

Bristol-Myers Squibb Services Unlimited CompanyUnresectable or Metastatic Colorectal Cancer, Untreated

Target: 33Updated: 2026-03-11